Condition
Post-Transplant Lymphoproliferative Disease
Total Trials
3
Recruiting
0
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
200%
2 of 1 completed with results
Key Signals
2 with results50% success
Data Visualizations
Phase Distribution
3Total
Early P 1 (1)
P 2 (2)
Trial Status
Completed1
Terminated1
Active Not Recruiting1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT03131934Early Phase 1Active Not RecruitingPrimary
Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant
NCT01964755Phase 2Terminated
Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma
NCT01058239Phase 2CompletedPrimary
Bortezomib Plus Rituximab for EBV+ PTLD
Showing all 3 trials